Cellerant Therapeutics, Inc., a clinical stage biotechnology company, focuses on the regulation of the hematopoietic (blood-forming) system. It develops human stem cell and antibody therapies for oncology applications and blood-related disorders. The company’s pipeline products include CLT-008, an off-the-shelf cell-based therapy for the treatment of neutropenia associated with chemotherapy in oncology patients, cord blood transplantation, and acute radiation exposure; and a cancer stem cell antibody discovery program focused on therapies for acute myeloid leukemia, multiple myeloma, and myelodysplastic syndrome. Cellerant Therapeutics, Inc. was formerly known as Celtrans, LLC. The company w...
1561 Industrial Road
San Carlos, CA 94070
Founded in 2001
Cellerant Therapeutics, Inc. Announces Preclinical Data Showing Potent Killing of Leukemic Blast and Stem Cells by CSC030-ADC
Oct 11 16
Cellerant Therapeutics, Inc. announced preclinical data showing potent killing of leukemic blast and stem cells by CSC030-ADC, the company’s antibody drug-conjugate (ADC) product candidate being developed as a treatment for acute myeloid leukemia (AML). CSC030-ADC targets CSC030, or the C-type-like lectin 1 (CLL-1), a cell surface antigen widely expressed in nearly all AML cell subtypes, including leukemic stem cells. However, CSC030 is not expressed on normal hematopoietic stem and progenitor cells, making it a highly attractive target for an AML therapeutic. The data was presented by Jagath Reddy Junutula, Ph.D., Vice President, Antibody Discovery & Development of Cellerant Therapeutics, at the 7th Annual World ADC meeting being held in San Diego, October 10-13, 2016. CSC030-ADC is a humanized monoclonal ADC that utilizes a potent DNA-damaging payload to target CSC030, an antigen expressed specifically on AML blasts and leukemic stem cells. The company and others have shown that CSC030 is expressed in approximately 90% of all AML patient types, including all French American British (FAB) classifications, all cytogenetic risk categories, and in patients independent of FLT-3 status. When combined with a cytotoxic payload, the CSC030-ADC displayed potent target-dependent activity on several AML cell lines and robust tumor colony inhibition. CSC030-ADC also demonstrated a broad therapeutic index, e.g., greater than 10-fold therapeutic efficacy to toxicity, in AML tumor models. In addition, CSC030-ADC showed killing of both proliferating and quiescent CSC030-expressing cells. Importantly, CSC030 is not expressed on normal hematopoietic stem or progenitor cells and thus should have minimal effect on the formation of normal blood cell types. In contrast, the CD33 antigen is expressed on both normal stem and progenitor cells.
National Cancer Institute Awards $1.5 Million SBIR Contract to Cellerant Therapeutics, Inc
Sep 26 16
Cellerant Therapeutics, Inc. announced that the National Cancer Institute has awarded the company a $1.5 million Small Business Innovation Research (SBIR) Phase II contract to support preclinical development of CSC012-ADC, a novel antibody drug-conjugate to treat acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The award will fund preclinical studies and other activities over the next two years which, if successful, will position the company to pursue an Investigational New Drug application for CSC012-ADC. This contract was awarded by the National Cancer Institute under the Small Business Research Innovation Research Program Contract Topic 326, 'Development of Novel Therapeutic Agents that Target Cancer Stem Cells'.